期刊文献+

冠状动脉支架内再狭窄的特征与高压球囊治疗 被引量:1

Angiographic Characteristics of In-stent Restenosis and High Pressure Balloon Angioplasty
下载PDF
导出
摘要 目的分析冠状动脉支架内再狭窄的特征和高压球囊扩张治疗的临床效果。方法对7例支架内再狭窄病例进行冠状动脉造影图像分析,其中6例施行高压球囊扩张治疗。结果68例冠脉内支架术患者中,有7例经冠状动脉造影证实为支架内再狭窄,发生率为10.29%,出现在术后1.5~8个月。靶血管在左前降支6例,右冠状动脉1例,病变特征表现为支架内弥漫狭窄的5例,局限性狭窄2例。除1例左前降支弥漫性狭窄外,余6例用12~15个大气压球囊扩张术治疗。术前狭窄程度平均为84%(75~98%),术后狭窄降至12%(0~35%),最小管腔内径从术前的平均0.52mm增至2.68mm。术中无严重并发症,1例在术后2个月发生再狭窄行CABG术,余5例随访6个月无心肌缺血复发。结论支架内再狭窄病变可表现为弥漫性和局限性二种。高压球囊扩张术治疗支架内再狭窄是简单可行的,能获得满意的即刻造影结果和较好的远期疗效。 Objective To analyze the angiographic characteristics of in - stent restenosis and evaluate the clinical efficacy Of high pressure expandable balloon for treatment of in - stent restenosis. Methods Analyses were made on the coronary angiograms of 7 in- stent restenosis cases, 6 Of whom underwent high pressure angioplasty. Results Out of 68 cases, 7 cases were found to have in - stent restenosis (10. 29% ) which occurred between 1. 5 to 8 months after the stent implantation. The target vessels of 6 cases were in the left anterior descending arteries (LAD) and 1 case in the right coronary artery. In 5 cases, diffused stenosis was found in the stent while 2 cases had focal stenosis. Out of 7 restenosis cases, 6 underwent high pressure balloon inflation. After the balloon angioplasty, the minimal lumen diameter (MLD) of the stenostic coronary segment was increased from 0. 52 mm to 2. 68 mm and the stenostic degree was reduced from 84% (75 - 98% ) to 12 (0 - 35% ). No severe complications were revealed. During 6 months of follow - up, one case had restenosis after 2 months of balloon angioplasty and another five cases had no angina. Conclusion High pressure balloon angioplasty was a simple, safe and satisfactory treatment for in - stent restenosis.
出处 《浙江临床医学》 2000年第6期363-364,共2页 Zhejiang Clinical Medical Journal
关键词 支架内再狭窄 冠状动脉造影 球囊血管成形术 In-stent restenosis Coronary angiography Balloon angioplasty
  • 相关文献

参考文献8

  • 1KastratiA,SchomigA,eleziS,etal.predictivefactorsofrestenosisaftercoronarystentplacementJAmCollCardiol,1997,30:1428~1436.
  • 2HoffmannR,mintzGS,DrssaillantGR,etal.pattemsandmechanismsofIn-stentrestenosis.Circulation,1996,94:1247~1254.
  • 3StraussBH,UmansVA,vanSuylenRJ,etal.Derectionalatherectomyfortreatmentrestenosiswithincoronarystents:Clinical,angiographicandhistologicresults.AmjJCardiol,1992,20:1465~1473.
  • 4ottnerRK,HardiganKR.High-speedrotationlablationforin-stentrestenosis.CathetCardiovascDiagn,1997,40:144~149.
  • 5MehranR,MintzG,SatlerL,etal.TreatmentofinstentrestemosiswithexcimerlasercoronaryangioplastyMechanismandresultscomparedtoPTCAalone.Circulation,1997,96:2186~2189.
  • 6MacanderPJ,RoubinGS,AgarvalSK,etal.Balloonangioplastyfortreatmentofinstentrestenosis:feasiblility,safetyandefficacy,CathetCardiovascDiagn,1994,32:125~131.
  • 7GordonPC,GibsonCM,CohenDJ,etal.Mechanismsofrestenosisanbredilatationwithincoronarystents-quantitativeangiographicassessment.JAmerColl,Cardiol,1993,21:1166~1174.
  • 8SchieleF,MeneveauN,VuillemenotA,etal.lntracoronaryultrasoundassessmentofballoonangioplastyinintrastentrestenosis.JAmCollCardiol,1997,29:240A.

同被引文献17

  • 1赖琳,詹俊,李楚强,于钟,姚和瑞.大肠癌患者的临床、病理及预后分析576例[J].世界华人消化杂志,2007,15(9):1037-1040. 被引量:8
  • 2凌伟,颜亚平,李良月.结直肠癌预后影响因素分析:附112例报告[J].中国普通外科杂志,2007,16(9):923-925. 被引量:12
  • 3Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European society of cardiology (ESC) and the European society of anaesthesiology (ESA) [J]. Eur J Anaesthesiol, 2014, 31 (10): 517- 573.
  • 4Dernellis J, Panaretou M. Assessment of cardiac risk before non- cardiac surgery: brain natriuretic peptide in 1590 patients[J]. Heart, 2006, 92(11): 1645-1650.
  • 5Rodseth RN, Padayachee L, Biccard BM. A meta-analysis of the utility of pre-operative brain natriuretic peptide in predicting early and intermediate-term mortality and major adverse cardiacevents in vascular surgical patients[J]. Anaesthesia, 2008, 63(11): 1226-1233.
  • 6Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an Independent predictor of adverse cardiovascular outcomes within 30 days of non-cardiac surgery?A systematic review and meta-analysis of observational studies[J]. J Am Coll Cardiol, 2009(54): 1599-1606.
  • 7Guarracino F, Baldassarri R, Priebe Hi. Revised ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management, implications for preoperative clinical evaluation[J]. Minerva Anestesiol, 2015, 81(2): 226-233.
  • 8Fernando A, P6rez-Vizcayno JM, Alberto C, et al. A prospective randomized trial of Drug-Eluting balloons versus Everolimus- Eluting stents in patients with In-Stent restenosis of Drug-Eluting stents[J]. Am Coil Cardiol, 2015, 66(1): 23-33.
  • 9Alfonso F, Byrne RA, Rivero FA. Current treatment of In-Stent restenosis[J]. J Am Coll Cardiol, 2014, 63(24): 2659-2673.
  • 10Dangas GD, Claessen BE, Caixeta AA, et al. In-Stent restenosis in the Drug-Eluting stent era[J]. J Am Coil Cardiol, 2010, 56(23): 1897-1907.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部